VRTX - VERTEX PHARMACEUTICALS INC / MA
484.24
-1.930 -0.399%
Share volume: 1,406,954
Last Updated: Fri 21 Feb 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.34%
PREVIOUS CLOSE
CHG
CHG%
$486.17
3.91
0.01%
Fundamental analysis
70%
Profitability
95%
Dept financing
7%
Liquidity
75%
Performance
60%
Performance
5 Days
4.79%
1 Month
13.14%
3 Months
7.38%
6 Months
0.91%
1 Year
13.46%
2 Year
64.51%
Key data
Stock price
$484.24
DAY RANGE
$479.69 - $487.38
52 WEEK RANGE
$377.85 - $519.88
52 WEEK CHANGE
$11.71
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Recent news